Skip to main content Back to Top
Advertisement

11/25/2019

Levetiracetam Injection

Products Affected - Description

    • Levetiracetam injection, Athenex, 10 mg/mL, 100 mL premixed bag, 10 count, NDC 70860-0603-82
    • Levetiracetam injection, Athenex, 15 mg/mL, 100 mL premixed bag, 10 count, NDC 70860-0604-82
    • Levetiracetam injection, AuroMedics, 100 mg/mL, 5 mL vial, 10 count, NDC 55150-0177-05
    • Levetiracetam injection, Hikma, 100 mg/mL, 5 mL vial, 25 count, NDC 00143-9673-25
    • Levetiracetam injection, Pfizer, 100 mg/mL, 5 mL vial, 25 count, NDC 00409-1886-02
    • Levetiracetam injection, Sagent, 100 mg/mL, 5 mL vial, 10 count, NDC 25021-0780-05
    • Levetiracetam injection, X-Gen, 100 mg/mL, 5 mL vial, 10 count, NDC 39822-4000-01

Reason for the Shortage

    • American Regent did not provide a reason for the shortage.
    • Athenex did not provide a reason for the shortage.
    • AuroMedics did not provide a reason for the shortage.
    • Fresenius Kabi has product available.
    • Mylan has levetiracetam injection available.
    • Pfizer did not provide a reason for the shortage.
    • Sagent has product available.
    • Sun Pharma are not manufacturing levetiracetam injection at this time.
    • UCB has product available.
    • Hikma did not provide a reason for the shortage.
    • X-Gen has product available.

Available Products

    • Keppra injection, UCB, 100 mg/mL, 5 mL vial, 10 count, NDC 50474-0002-63
    • Levetiracetam injection, Athenex, 5 mg/mL, 100 mL premixed bag, 10 count, NDC 70860-0602-82
    • Levetiracetam injection, AuroMedics, 10 mg/mL, 100 mL premixed bag, 10 count, NDC 55150-0247-47
    • Levetiracetam injection, AuroMedics, 15 mg/mL, 100 mL premixed bag, 10 count, NDC 55150-0248-47
    • Levetiracetam injection, AuroMedics, 5 mg/mL, 100 mL premixed bag, 10 count, NDC 55150-0246-47
    • Levetiracetam injection, Fresenius Kabi, 100 mg/mL, 5 mL vial, 10 count, NDC 63323-0400-05
    • Levetiracetam injection, Mylan, 10 mg/mL, 100 mL premixed bag, 10 count, NDC 67457-0265-10
    • Levetiracetam injection, Mylan, 15 mg/mL, 100 mL premixed bag, 10 count, NDC 67457-0266-10
    • Levetiracetam injection, Mylan, 5 mg/mL, 100 mL premixed bag, 10 count, NDC 67457-0255-10

Estimated Resupply Dates

    • Athenex has levetiracetam 10 mg/mL and 15 mg/mL 100 mL premixed bags on allocation.
    • AuroMedics has levetiracetam 100 mg/mL 5 mL vials on intermittent back order and the company is releasing product as it becomes available.
    • Hikma has 100 mg/mL 5 mL vials on back order and the company estimates a release date of early-December 2019.
    • Pfizer has levetiracetam 100 mg/mL 5 mL vials on back order and the company estimates a release date of November 2019.
    • Sagent has short-dated levetiracetam 100 mg/mL 5 mL vials with an expiration date of March 2020.
    • X-Gen has levetiracetam 100 mg/mL 5 mL vials on back order and the company estimates a release date of early-December 2019.

Updated

Updated November 25, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 14, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins